Cocrystal Pharma (NASDAQ:COCP) Shares Down 5.6% – Time to Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP) fell 5.6% during trading on Monday . The stock traded as low as $1.17 and last traded at $1.17. Approximately 23,073 shares traded hands during trading, a decline of 59% from the average session volume of 56,429 shares. The stock had previously closed at $1.24.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Cocrystal Pharma presently has an average rating of “Sell”.

Cocrystal Pharma Stock Down 5.6%

The business has a fifty day moving average price of $1.05 and a 200-day moving average price of $1.13. The company has a market cap of $22.53 million, a P/E ratio of -1.54 and a beta of 1.48.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million. As a group, research analysts expect that Cocrystal Pharma, Inc. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new position in Cocrystal Pharma stock. T3 Companies LLC purchased a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned approximately 0.38% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. 6.72% of the stock is currently owned by institutional investors and hedge funds.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.